545,132 Shares in Maze Therapeutics, Inc. $MAZE Acquired by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC bought a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 545,132 shares of the company’s stock, valued at approximately $14,135,000. ArrowMark Colorado Holdings LLC owned about 1.13% of Maze Therapeutics as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of MAZE. Vanguard Group Inc. increased its position in shares of Maze Therapeutics by 218.1% during the third quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock worth $34,615,000 after purchasing an additional 915,342 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Maze Therapeutics by 3,868.5% during the 3rd quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock valued at $20,166,000 after purchasing an additional 758,104 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its position in shares of Maze Therapeutics by 10.6% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after purchasing an additional 438,274 shares in the last quarter. Balyasny Asset Management L.P. acquired a new stake in shares of Maze Therapeutics in the 3rd quarter worth $11,246,000. Finally, Washington University purchased a new position in Maze Therapeutics during the 3rd quarter worth $5,463,000.

Insider Buying and Selling at Maze Therapeutics

In other news, SVP Amy Bachrodt sold 5,000 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $46.04, for a total value of $230,200.00. Following the transaction, the senior vice president directly owned 12,965 shares of the company’s stock, valued at approximately $596,908.60. This represents a 27.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Atul Dandekar sold 7,500 shares of the stock in a transaction dated Thursday, January 29th. The shares were sold at an average price of $44.27, for a total value of $332,025.00. Following the completion of the transaction, the insider directly owned 10,503 shares in the company, valued at $464,967.81. This represents a 41.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 230,000 shares of company stock worth $9,768,292.

Maze Therapeutics Price Performance

NASDAQ MAZE opened at $50.21 on Friday. The company has a market cap of $2.42 billion, a price-to-earnings ratio of -2.40 and a beta of 4.47. The stock’s fifty day moving average price is $44.82 and its 200 day moving average price is $35.75. Maze Therapeutics, Inc. has a 1 year low of $6.71 and a 1 year high of $52.86.

Analyst Upgrades and Downgrades

MAZE has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating on shares of Maze Therapeutics in a research note on Wednesday, January 28th. Lifesci Capital upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Guggenheim upped their price objective on shares of Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Wells Fargo & Company assumed coverage on shares of Maze Therapeutics in a research report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price objective for the company. Finally, Mizuho upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Maze Therapeutics currently has a consensus rating of “Buy” and an average target price of $54.63.

Maze Therapeutics Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.